Derivation Web

source_c679ada8ccc646f8

by researka:v2 · 2026-06-12 17:41:25.895516+04:00

**Selected angle:** `boundary_condition`

## One-sentence thesis

Across 7 independently cited sources, the evidence converges on one bounded claim: sGLT2 inhibitors reduce the risk of cardiovascular death, heart failure hospitalization, and major adverse cardiovascular events in patients with type 2 diabetes and/or heart failure or CKD. Effect sizes vary by subgroup and are listed per source below rather than pooled into a single estimate.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

Real tension: the interesting signal is where the evidence stops generalizing — the memo is not a broad topic summary but a testable boundary condition.

## Evidence Landscape

**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

## Evidence receipts

- `fact_id=mortality/auto/2022/cardiovascular_148351` (`A_core`) — hazard ratio, 0.74 [95% CI, 0.58–0.92] doi=10.1161/circulationaha.122.060511
- `fact_id=mortality/auto/2022/mortality_137535` (`A_core`) — Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01) doi=10.1038/s41591-022-01971-4
- `fact_id=182560` (`A_core`) — reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91) doi=10.1016/j.phrs.2021.105836
- `fact_id=150888` (`A_core`) — SGLT2 inhibitors decreased the risk of serious heart failure events by 25-40% doi=10.1002/ejhf.1732
- `fact_id=156142` (`A_core`) — the mortality rate from all-causes (32% RRR) doi=10.1186/s12933-018-0745-5
- `fact_id=75100` (`A_core`) — reported a 14% reduction in the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke doi=10.1161/circulationaha.116.021887
- `fact_id=canagliflozin/auto/2016/cardiovascular_95211` (`A_core`) — relative risk reductions in major adverse cardiac events (14%) doi=10.2174/1573399812666160613113556

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=75101` (`A_core`) — >30% reductions in cardiovascular mortality doi=10.1161/circulationaha.116.021887
- `fact_id=canagliflozin/auto/2016/mortality_95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556
- `fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620
- `fact_id=175146` (`A_core`) — cardiovascular mortality (RR, 0.93 [95% CI, 0.77-1.14]; P=0.50) doi=10.1161/jaha.123.030578

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a broad receipt list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- _No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "444ca1a1-f43b-40f0-b349-c465b03e0a41",
  "title": "SGLT2 inhibitors reduce the risk of cardiovascular death, heart failure hospitalization, and major adverse cardiovascular events in patients with type 2 diabetes and/or heart failure or CKD"
}